Searched over 200M research papers for "lisinopril dose"
10 papers analyzed
These studies suggest lisinopril is effective and well-tolerated across various doses (2.5-80 mg) for treating hypertension, heart failure, and in pediatric patients, with higher doses offering additional benefits up to 40 mg, beyond which no further benefits are observed.
20 papers analyzed
Lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, is widely used to manage hypertension and related conditions such as heart failure and diabetic nephropathy. The optimal dosage of lisinopril varies depending on the condition being treated, patient demographics, and individual response to the medication.
In patients with mild to moderate essential hypertension, lisinopril demonstrates a clear dose-response relationship. Studies have shown that doses of 10 mg and 20 mg per day produce similar peak antihypertensive effects, which are significantly greater than those achieved with a 2.5 mg dose but less than those with an 80 mg dose . The antihypertensive response at 24 hours post-dose is dose-related across the 2.5 to 80 mg per day range.
Higher doses of lisinopril, such as 80 mg per day, have been shown to be well-tolerated and effective in reducing both supine and erect blood pressure in patients with essential hypertension. However, the incidence of first-dose symptomatic hypotension does not significantly increase with an initial dose of 20 mg compared to 10 mg, suggesting that starting at 20 mg may not pose additional risk.
In hypertensive children aged 6 to 16 years, lisinopril has been found to be effective and well-tolerated. An initial dose of 0.07 mg/kg once daily effectively lowers blood pressure within two weeks, with a clear dose-response relationship observed across different weight-based dosing regimens. Pharmacokinetic studies in children have further supported the use of weight-adjusted dosing to optimize therapeutic outcomes .
In type 1 diabetic patients with diabetic nephropathy, higher doses of lisinopril (40 mg per day) have been shown to offer additional reductions in urinary albumin excretion rate (UAER) and blood pressure compared to the standard 20 mg dose. However, increasing the dose to 60 mg does not provide further benefits. This suggests that 40 mg per day is the optimal dose for renoprotection in these patients.
Lisinopril has been demonstrated to be effective in improving clinical outcomes in patients with congestive heart failure. Doses ranging from 2.5 to 20 mg per day significantly improve exercise duration, left ventricular ejection fraction, and other clinical parameters compared to placebo . High-dose lisinopril (32.5-35 mg per day) has also been shown to reduce all-cause mortality and hospitalization rates in high-risk heart failure patients, including those with diabetes mellitus.
In obese hypertensive patients, lisinopril has been found to be as effective as hydrochlorothiazide in lowering blood pressure. However, lisinopril may offer additional benefits, such as a more favorable impact on metabolic parameters, making it a suitable monotherapy option for patients at high risk of metabolic disorders.
Lisinopril is a versatile and effective antihypertensive agent with a well-established dose-response relationship. Optimal dosing varies by condition and patient population, with higher doses providing additional benefits in certain cases such as diabetic nephropathy and heart failure. Careful consideration of patient-specific factors, including weight and renal function, is essential for maximizing therapeutic outcomes and minimizing adverse effects.
Most relevant research papers on this topic